Dr Hendrik-Tobias Arkenau

  • Qualifications
    MD, PhD
  • NHS Base
    Director of Drug Development, Sarah Cannon Research UKHonorary Consultant, University College London Hospitals NHS FoundationTrust
  • Speciality
    Medical oncology
  • Sub speciality
    Gastrointestinal cancers, melanoma
  • Year qualified
    2000
  • Research interests
    Clinical trials for new cancer drugs
  • Languages
    English and German
  • Biography

    Dr Arkenau received his medical and postgraduate degree at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before being appointed as Medical Director at Sarah Cannon Research UK, he was Senior Clinical Fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

    Dr Arkenau specialises in drug development of new cancer treatments and is Lead Investigator on various Phase-I and II trials. His clinical interests are gastrointestinal cancers (bowel, stomach, oesophagus, pancreas, liver) and melanoma. Dr Arkenau has published his research in various high-ranking peer-reviewed medical journals and textbooks and regularly presents research updates on new cancer treatments at national and international conferences.